Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Operating Expenses data on file, last reported at $17.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 22.22% year-over-year to $17.8 million in Q1 2026; TTM through Mar 2026 was $55.2 million, a 43.78% increase from a year earlier, with the FY2025 full-year figure at $52.0 million, up 81.8% from the prior year.
• Operating Expenses for Q1 2026 stood at $17.8 million, up from $13.8 million in the prior quarter.
• Over the last five years, Operating Expenses for IKT reached as high as $17.8 million in Q1 2026 and fell as low as $4.4 million in Q4 2022.
• Historically, Operating Expenses has averaged $8.1 million across 5 years, with a median of $5.1 million in 2024.
• Across the five-year window, Operating Expenses slipped 20.07% in 2024 and soared 205.25% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $4.4 million in 2022, then rose by 0.11% to $4.4 million in 2023, then soared by 193.6% to $12.9 million in 2024, then advanced by 6.55% to $13.8 million in 2025, then rose by 29.52% to $17.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $17.8 million in Q1 2026, $13.8 million in Q4 2025, and $12.8 million in Q3 2025.